Chinese authorities approve seasoned Novo Nordisk combination treatment

A 2022 New Year's resolution for Novo Nordisk will be to launch the combination treatment type 2 diabetes, Xultophy, in China, a goal made possible by the national authority's approval of the seven-year-old drug.

The treatment Xultophy, which combines Novo Nordisk's long-acting insulin Tresiba with the GLP-1 analog Victoza, is now headed to the Chinese market.

In Wednesday's report for the third quarter of the year, Novo Nordisk reports that the Chinese health authority, China National Products Administration (NMPA), has approved of the injection therapy for type 2 diabetes.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs